Black Cohosh is the best-studied herbal medicine for menopausal vasomotor symptoms in the European phytotherapy tradition. It holds "well-established use" status from the EMA/HMPC, a positive Commission E monograph, and an ESCOP monograph. The primary commercial product, Remifemin (isopropanolic extract, 40 mg/day), has demonstrated efficacy comparable to low-dose conjugated estrogens in some trials. The mechanism is non-estrogenic, acting through serotonergic, dopaminergic, and GABAergic pathways. The hepatotoxicity debate, which generated significant regulatory concern in the mid-2000s, has been largely resolved: rigorous causality assessments found no probable causal link in the vast majority of reported cases, with product adulteration and confounding factors implicated instead.

Cramp bark (Viburnum opulus) is one of the most traditional Western herbal antispasmodics, used primarily for dysmenorrhea (menstrual cramps) and other smooth muscle spasms. It is listed in the British Herbal Pharmacopoeia, the American Herbal Pharmacopoeia, and was included in the United States Pharmacopoeia from 1894 and the National Formulary from 1916. The key compound viopudial, a coumarin unique to V. opulus, provides musculotropic spasmolytic activity on uterine and other smooth muscle, complemented by scopoletin (shared with the related black haw, V. prunifolium). Despite centuries of traditional authority and a coherent pharmacological rationale, virtually no modern clinical trials exist -- making cramp bark one of the starkest examples of the gap between traditional reputation and evidence-based validation. It is generally well-tolerated with a favorable safety profile when the bark (not berries) is used.

Dong Quai (Angelica sinensis) is one of the most important herbs in Traditional Chinese Medicine (TCM) for women's health, earning the title "female ginseng." However, from the European evidence-based phytotherapy perspective, it represents the weakest herb in this collection. The EMA/HMPC explicitly REJECTED adoption of a monograph due to inadequate evidence of 30+ years of use in the EU, toxicological concerns, and the need for medical supervision. There is no Commission E monograph. The only major RCT as a standalone treatment (Hirata 1997, n=71) showed no benefit over placebo for menopausal symptoms. Significant safety concerns exist regarding anticoagulant interactions (documented potentiation of warfarin) and photosensitivity due to coumarin and furanocoumarin content. Dong Quai represents the largest gap between traditional reputation and evidence-based validation in this collection.

Evening Primrose Oil is one of the most widely used supplements for women's health, particularly for PMS and cyclical mastalgia. However, there is a notable gap between its consumer popularity and the strength of clinical evidence. The EMA/HMPC has granted only "traditional use" status, and only for dry skin conditions -- not for PMS or mastalgia. The active compound is gamma-linolenic acid (GLA), an omega-6 fatty acid precursor to anti-inflammatory prostaglandins. While some individual trials show positive results for mastalgia and PMS, systematic reviews and meta-analyses present mixed findings. The Cochrane review found insufficient evidence for atopic dermatitis. EPO represents a case where traditional reputation and consumer demand have outpaced scientific validation.

Raspberry Leaf has been used by midwives and herbalists for centuries to prepare the uterus for labor and ease childbirth. However, this is one of the most significant disconnects between traditional practice and evidence in European phytotherapy. The EMA/HMPC has granted "traditional use" status -- but specifically for menstrual spasms, mouth/throat inflammation, and diarrhea, NOT for pregnancy or labor facilitation. The EMA explicitly does NOT recommend the traditional parturition use. Clinical evidence is sparse: only two small clinical studies and one recent observational study exist for pregnancy use, none of which provides definitive evidence of efficacy or safety. The active constituents (fragarine, tannins, flavonoids) are poorly characterized. A well-designed RCT is urgently needed.

Red Clover is a significant source of isoflavones (formononetin, biochanin A, genistein, daidzein) used primarily for menopausal hot flashes. Unlike soy isoflavones, Red Clover contains higher proportions of the methylated isoflavones formononetin and biochanin A. Meta-analyses show a statistically significant reduction in hot flash frequency (-1.73/day vs. placebo), with best results at doses of 80+ mg isoflavones/day for 12+ weeks. However, formal European regulatory recognition is limited -- there is no Commission E or ESCOP monograph specifically for menopausal use, and the EMA assessment is not as developed as for Black Cohosh or Vitex. Promensil is the most studied commercial product. Safety appears acceptable for up to 2 years, but uncertainty persists regarding use in hormone-sensitive cancers.

Sage is a well-established European medicinal herb approved by Commission E, ESCOP, and EMA for excessive perspiration (especially menopausal hot flashes and night sweats), inflammation of the mouth and throat, and mild dyspeptic complaints. The leaf contains thujone-bearing essential oil alongside rosmarinic acid and other phenolic compounds. Clinical evidence for its anti-hydrotic (sweat-reducing) effect is moderate, supported by several open-label and a few controlled trials showing 50-64% reductions in hot flash intensity. Thujone content requires attention to dosage limits and duration; the EMA recommends limiting use of thujone-containing preparations to 2-4 weeks unless under medical supervision. Sage occupies a unique niche in phytotherapy as one of the few herbal medicines with a specific indication for hyperhidrosis.

Shatavari (Asparagus racemosus) is considered the foremost women's health tonic in Ayurveda, where it is called the "Queen of Herbs" and used across all stages of female reproductive life -- from menstruation through menopause and lactation. The tuberous root contains steroidal saponins (shatavarins I-IV), isoflavones, racemosol, and mucilage with demonstrated estrogenic, galactagogue, antioxidant, and adaptogenic properties in preclinical studies. Limited clinical trials suggest modest benefits for lactation promotion (galactagogue effect) and menopausal symptoms. The name "Shatavari" translates to "she who possesses a hundred husbands," reflecting its traditional reputation as a female reproductive tonic and aphrodisiac. No European regulatory monographs exist, but shatavari is one of the most important herbs in the Ayurvedic Pharmacopoeia. Evidence is limited -- pharmacologically promising with deep traditional roots but insufficient clinical trial data by Western standards.

Soy Isoflavones are the most extensively studied phytoestrogens for menopausal symptoms, with dozens of RCTs and multiple meta-analyses. A 2025 meta-analysis (12 RCTs, n=533) confirms a statistically significant but modest effect on menopausal symptoms (Hedges' g = -0.25). However, a landmark 2024 meta-analysis demonstrated that soy isoflavones have NO effect on four key estrogenicity markers (endometrial thickness, vaginal maturation index, FSH, estradiol), fundamentally challenging the "phytoestrogen" classification. The breast cancer question has shifted from concern to cautious reassurance -- epidemiological data shows reduced risk with dietary soy intake, and post-diagnosis consumption is associated with 25% reduced recurrence. Thyroid effects are minimal (modest TSH elevation, no clinical significance in euthyroid individuals). The equol producer status (approximately 30% of Western populations) may be a key determinant of individual response.

Spearmint (Mentha spicata) tea has demonstrated significant anti-androgenic effects in women with PCOS and hirsutism across several randomized controlled trials, consistently reducing free testosterone levels while increasing LH, FSH, and estradiol. The key active compounds include rosmarinic acid (the dominant polyphenol, comprising up to 88% of total phenolics), the monoterpene carvone, and limonene. Spearmint is notable for being a widely available, food-grade herb with a favorable safety profile and genuine therapeutic potential -- a rarity in phytotherapy. Emerging evidence from double-blind RCTs also supports the use of high-polyphenol spearmint extract (900 mg/day) for cognitive enhancement, particularly working memory and attention in older adults and active populations.

Vitex agnus-castus is the premier European phytomedicine for premenstrual syndrome (PMS), cyclical mastalgia, and menstrual irregularities. It holds "well-established use" status from the EMA/HMPC and a positive Commission E monograph. Its mechanism is uniquely well-characterized among gynecological herbs: diterpenes (clerodadienols) act as dopamine D2 receptor agonists, reducing prolactin secretion from the anterior pituitary. This explains its efficacy in conditions linked to latent hyperprolactinemia. The Ze 440 extract (Zeller, 20 mg/day) and BNO 1095 extract (Bionorica) are the best-studied preparations. Meta-analyses of 13-14 controlled trials consistently show benefit for PMS symptom reduction.

White peony root (Bai Shao) is one of the most important gynecological herbs in Traditional Chinese Medicine, appearing in dozens of classical formulas for menstrual disorders, pain, and blood deficiency. Its principal active compound, paeoniflorin (a monoterpene glycoside comprising over 90% of Total Glucosides of Peony), has well-characterized anti-inflammatory, immunomodulatory, and antispasmodic properties. Clinical evidence comes primarily through classical combination formulas: Shakuyaku-kanzo-to (peony-licorice decoction) is used in Japan for acute muscle cramps, while Dang Gui Shao Yao San is studied for dysmenorrhea and gynecological complaints. Total Glucosides of Peony (TGP) is an approved drug in China since 1998 for rheumatoid arthritis adjunctive therapy, with meta-analyses supporting its efficacy combined with DMARDs and its hepatoprotective properties. Emerging preclinical and early clinical evidence suggests potential in PCOS via anti-androgenic mechanisms and in systemic lupus erythematosus.